

Statement of Deposit for 0975.1005-016.doc  
DES/CD/ewin  
December 19, 2005

PATENT APPLICATION  
Attorney's Docket No.:0975.1005-016



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David Knight and  
Scott Siegel

Application No.: 10/044,534 Group: 1644

Filed: January 10, 2002 Examiner: Phillip Gabel

Confirmation No.: 4929

For: METHODS OF TREATING ANKYLOSIS WITH CHIMERIC ANTI-TNF  
ANTIBODIES

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
12-29-05	Dawn M Myers
Date	Signature
Dawn M Myers	
Typed or printed name of person signing certificate	

STATEMENT UNDER 37 C.F.R. §1.804, §1.806 AND §1.808

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. §1.804, §1.806 and §1.808, the undersigned states as follows:

1. Murine mAb A2 (c134A) was deposited on September 22, 2005, and assigned ATCC Accession Number PTA-7045. The above-referenced application specifically identifies this biological deposit, which was deposited under the Budapest Treaty at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209. I am a person in position to corroborate that the biological material which was deposited is a biological material

BEST AVAILABLE COPY

10/04 14

- 2 -

specifically identified in the priority application U.S. Serial No. 07/670,827, filed March 18, 1991, as filed.

2. Deposit PTA-7045 will be maintained in a public depository for the enforceable life of the patent which issues from the above-referenced application, a term of at least thirty years from the date of deposit or at least five years after the most recent request for the furnishing of a sample of the deposit is received by the depository, whichever is longer.
3. In accordance with 37 C.F.R. §1.808(a)(1), access to deposit PTA-7045 will be available during the pendency of the above-referenced application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122.
4. In accordance with 37 C.F.R. §1.808(a)(2), and except as permitted by 37 C.F.R. §1.808(b), all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent on the above-referenced application.

Respectfully submitted,

By G. Kevin Townsend  
G. Kevin Townsend

Dated: December 28, 2005

# Peptides

## Chemistry and Biology

Proceedings of the Tenth American Peptide Symposium  
May 23-28, 1987, St. Louis, Missouri, U.S.A.

Edited by

**Garland R. Marshall**

Department of Pharmacology  
Washington University School of Medicine  
St. Louis, Missouri 63110, U.S.A.



ESCOM • Leiden • 1988

EXHIBIT

## A synthetic strategy for epitope mapping

H. Mario Geysen, Stuart J. Rodda and Tom J. Mason  
Commonwealth Serum Laboratories, 45 Poplar Road, Parkville, Victoria 3052, Australia

### Introduction

Synthetic peptides are attractive as probes for studying aspects of immunology at the molecular level, as possible diagnostic reagents, as characterized vaccine components and as hormone analogs. With the need for larger numbers of peptides for evaluation, fully automated synthesizers are widely used, and several methods have been described for the simultaneous synthesis of many peptides [1].

We describe a procedure allowing several thousand peptides to be concurrently synthesized at the rate of one residue coupled per day. With no practical restriction on the number of peptides which can be synthesized, a completely systematic approach to the location of epitopes (scan; Fig. 1) and their further resolution (replacement set; Fig. 2) becomes possible [2]. Good agreement has been shown between the results obtained from these rod-synthesized peptides and those from conventionally synthesized and purified peptides [3]. The stability of the rod-synthesized peptides on repeat testing allows their reuse for 30-60 tests.

This method has created the opportunity to address questions, which were formerly thought to be too difficult to answer, about the location of epitopes and their specificity for antibody.

### Synthesis of Peptides

The method of peptide synthesis on rods has been described in detail elsewhere [2]. Briefly, specially-molded high-density polyethylene rods (diameter 4 mm) were suspended in deaerated 6% (v/v) acrylic acid in water containing 0.005 M CuSO<sub>4</sub>. Gamma-irradiation at a dose of 0.8 Mrad was used to graft polymerize the monomer to the rods as polyacrylic acid. After a wash cycle, dried grafted rods were assembled into specially molded polyethylene holders designed to hold 96 rods in the format and spacing of a microtiter plate. Subsequent reactions at the tips of the rods were carried out in the wells of a specially molded polyethylene tray.

An amino group was introduced by reacting the polyacrylic acid on the rods for 2-3 days with mono-(Boc)-1,6-diaminohexane in DMF using DCC to achieve the condensation. Following a conventional Boc-deprotection cycle with TFA




Fig. 1. Profiles of antigenic response (A-C) as a function of all possible sperm whale myoglobin (SWMb) hexapeptides. Each parameter is plotted as the sequence number corresponding to the first residue (amino-terminal) of the relevant hexapeptide. (A) Scan obtained from an individual rabbit anti-SWMb serum, used at a dilution of 1/400. The vertical axis shows the absorbance obtained at the end of the ELISA. (B) The individual titer (square) or, where more than one serum reacted, the geometric mean titer (circle) and the range of titers (vertical bar) of the antisera. Titers less than 200 (twice the slope of the test background) were ignored. (C) The frequency of the antigenic response given by the number of rabbit antisera that react with each hexapeptide.




Fig. 2. Replacement set analysis, based on parent pentapeptide  $^{14}\text{HFTHE}^{15}$  homologous with myohemerythrin. Each block of 20 ELISA values represents the results with peptides containing the single amino acid substitution identified by the single letter code beneath each bar. The position of the substitution is indicated by an asterisk in the sequence given under that block. The homologous amino acid is emphasized. ELISA values for the five copies of the parent sequence have been averaged and taken as 100% for the purposes of comparison with replacement analogs. Dilution of rabbit antiserum used was 1/1000.

Boc- $\beta$ -alanine was coupled for a limited time to a target density of  $50 \pm 10$  nmol per rod tip. Unreacted amino groups were acetylated by reaction with acetic anhydride in DMF/TEA. Successive DCC/HOBt-mediated coupling reactions were carried out overnight using side-chain protected amino acids as dictated by the sequence to be synthesized. A microcomputer program was used to calculate the requirements for the preparation of the activated amino acid solutions, and to direct the addition of the correct amino acid to each rod on each day. At the completion of the final coupling reaction, and after removal of the Boc group, the terminal amino group was acetylated. Side-chain deprotection was achieved by reaction with 50 mM boron tris(trifluoroacacetate) in dry TFA [4].

#### Detection of Binding of Antibody by the Rod-Coupled Peptides

ELISA reactions were carried out with the appropriate serum and conjugate solutions in polystyrene microtiter trays [1]. Briefly, the tips of the rods, with the peptides still attached, were precoated using a 2% protein solution to block nonspecific adsorption of antibodies. Rods were incubated overnight in an appropriate dilution of an antiserum, washed 4 times, and incubated for 1 h in 'conjugate', comprising horseradish peroxidase-labeled goat anti-Ig, specific for the antibody species under test.

After washing to remove unbound conjugate, the level of bound conjugate was determined by the color developed by the reaction with a solution of the enzyme substrate, hydrogen peroxide in phosphate/citrate buffer, pH 4.0.

containing ABTS. Bound antibody was removed from the rods prior to retesting with another antiserum.

#### **Rationale of Strategy**

The procedure for the synthesis of peptides as described was conceived in order to provide the very large numbers of peptides required for systematic screening for sequences with biological activity. As such, the following factors were considered:

(1) By ELISA, the detection of binding of antibody only requires peptide to be present in the range of picomol [5]. This condition is satisfied by the level of peptide produced on the tips of the rods, which is typically 30–50 nmol. Furthermore, we have observed comparable test absorbances for peptide densities varying over two orders of magnitude, indicating that the test is only limited by the concentration of antibody.

(2) As in the case with the majority of serological tests, where a given antigen is determined in the presence of a large excess of extraneous protein, absolute purity of a peptide is also not a necessary requirement. The specificity of the antibody is relied upon to distinguish between the nominal sequence synthesized and the inevitable small amounts of deletion sequences, termination peptides, or other byproducts formed during the synthesis.

(3) Large numbers of 'negative control sequences' are a natural consequence of the systematic way in which peptide sets are structured. As is the usual case, peptide sets consist of closely related sequences differing by only one or two amino acids from each other. The observation of antibody binding to one peptide but failing to bind to a closely related peptide is taken as good evidence for the specificity of the test.

#### **Stability on Repeat Testing**

As a consequence of the synthesis strategy in which completed peptide remains covalently coupled to the plastic support, reuse of peptide through a number of tests only requires removal of reacting antibody between tests. When the absolute value of the absorbance is monitored over many successive tests with the same peptides, a gradual decrease is observed. Experience with many sets of peptides suggests that 30–60 useful tests can be expected before it becomes necessary to resynthesize a particular set of peptides. Peptides have been stored (dry at 4°C) for extended periods between tests, without detectable loss of activity.

#### **Discussion**

The possibility that synthetic peptides may find uses as vaccines, diagnostics

and other biologically relevant agents has focused interest on methods which provide for large numbers of peptides for evaluation. It is our experience that using the methods described, a small laboratory could readily prepare more than 1000 peptides per month. Furthermore, the format of these peptides makes them ideally suited for repeated evaluation, and utilizes the same instrumentation as is routinely used for immunological testing. Identification of a peptide(s) with the desired properties can then be followed by the preparation of larger and well-characterized qualities, using well-established solid phase synthesis procedures.

References

1. Houghten, R.A., Proc. Natl. Acad. Sci. U.S.A., 82 (1985) 5131.
2. Geysen, H.M., Rodda, S.J., Mason, T.J., Tribbick, G. and Schoofs, P.G., J. Immunol. Methods, in press.
3. Geysen, H.M., Tainer, J.A., Rodda, S.J., Mason, T.J., Alexander, H., Getzoff, E.D. and Lerner, R.A., Science, 235 (1987) 1184.
4. Pless, J. and Bauer, W., Angew. Chem., 85 (1973) 142.
5. Bittic, J.L., Houghten, R.A., Alexander, H., Shinnick, T.M., Sutcliffe, J.G., Lerner, R.A., Rowlands, D.J. and Brown, F., Nature, 298 (1982) 158.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**